GlassScriptPhysician profile
Richard L Roseman
NPI 1407814205
$1,606.28
in general payments reported to CMS, 2019-2025
18 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $104 · 2021: $199 · 2022: $225 · 2023: $185 · 2024: $335 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $551.58 | 2021-2025 | |
| Pfizer INC. | $237.09 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.33 | 2019-2024 | Airsupra |
| Idorsia Pharmaceuticals US INC | $143.03 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $99.45 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $71.41 | 2023-2024 | Trelegy Ellipta |
| Amgen INC. | $51.06 | 2025 | Repatha |
| Allergan, INC. | $46.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.55 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.09 | 2021-2023 | Xifaxan |
| Eisai INC. | $22.44 | 2024 | |
| Novo Nordisk INC | $21.80 | 2025 | |
| Almatica Pharma LLC | $18.16 | 2022 | |
| Athena Bioscience, LLC | $16.41 | 2024 | Nexiclon Xr |
| Collegium Pharmaceutical, INC. | $16.26 | 2024 | Belbuca |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $16.02 | 2025 | Ibsrela |
| Exact Sciences Corporation | $15.22 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Roseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.